Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study
Scientific Reports
Abstract
Dapagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, provides glycemic control and has proven cardiovascular and renal benefits in large trials, but its real-world use in Sudan has not been described.
The paper
Nasreldeen M, Mohamed TK, Babiker A et al.
Scientific Reports · 4 Oct 2026 · CC BY